Asset Planning Inc Buys 1,015 Shares of Edwards Lifesciences Corporation $EW

Asset Planning Inc raised its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,948 shares of the medical research company’s stock after acquiring an additional 1,015 shares during the period. Edwards Lifesciences comprises approximately 1.6% of Asset Planning Inc’s investment portfolio, making the stock its 14th largest holding. Asset Planning Inc’s holdings in Edwards Lifesciences were worth $2,186,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Quantbot Technologies LP bought a new position in Edwards Lifesciences during the 1st quarter valued at $26,000. SouthState Corp bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth $27,000. Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth $29,000. Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth $29,000. Finally, Global X Japan Co. Ltd. raised its stake in shares of Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after purchasing an additional 216 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Down 1.6%

EW stock opened at $74.02 on Friday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $43.46 billion, a PE ratio of 10.65, a PEG ratio of 3.55 and a beta of 1.05. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $83.00. The stock has a 50-day simple moving average of $78.09 and a two-hundred day simple moving average of $76.13.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on EW shares. Truist Financial lifted their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday. William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Robert W. Baird lifted their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.06.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.